Amikacin (BAY416651): Semi-Synthetic Aminoglycoside Antibiotic for Advanced Resistance Research

Executive Summary: Amikacin (BAY416651) is a semi-synthetic aminoglycoside antibiotic derived from kanamycin A, optimized for research on multidrug-resistant bacteria, especially carbapenem-resistant Enterobacter cloacae and Klebsiella pneumoniae (Chen et al., 2025). It inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, showing robust bactericidal effects (APExBIO). Amikacin is resistant to many aminoglycoside-modifying enzymes, but susceptible to acetylation by AAC (6')-I. It is water-soluble (≥5.86 mg/mL) and stable at -20°C, making it suitable for molecular and microbiology studies. APExBIO supplies Amikacin (B3431) for research use only.

Biological Rationale

Amikacin (BAY416651) was developed to address limitations of earlier aminoglycoside antibiotics, particularly susceptibility to enzymatic inactivation. This semi-synthetic derivative of kanamycin A is structurally modified to resist most aminoglycoside-modifying enzymes, including phosphotransferases and nucleotidyltransferases (APExBIO). Its primary role is to act as a potent bacterial protein synthesis inhibitor, targeting pathogens that have evolved multi-drug resistance (MDR), especially within the Enterobacteriaceae family. Amikacin's resilience against most resistance determinants is critical in studies of carbapenem-resistant Enterobacter cloacae and Klebsiella pneumoniae, which represent escalating threats in hospital and community settings (Chen et al., 2025). Research utilizing this compound provides insights into resistance transmission dynamics, especially where conventional aminoglycosides fail (see here). This article extends prior reviews by integrating new epidemiological and mechanistic findings from the post-2022 clinical landscape.

Mechanism of Action of Amikacin (BAY416651) Aminoglycoside Antibiotic

Amikacin acts by binding irreversibly to the 30S subunit of prokaryotic ribosomes. This interaction disrupts the initiation complex of protein synthesis and induces misreading of mRNA, leading to the production of aberrant or nonfunctional proteins (APExBIO). The result is rapid bactericidal activity. Amikacin's chemical modifications (notably the L-hydroxyaminobutyryl amide side chain at the N-1 position of the 2-deoxystreptamine ring) confer resistance to most aminoglycoside-inactivating enzymes, excluding AAC (6')-I acetyltransferases (protocols here). The compound's mechanism is highly conserved but can be compromised by specific enzyme-mediated acetylation, which reduces its ribosomal binding affinity. This sets amikacin apart from gentamicin and tobramycin, which are inactivated by a broader range of enzymes. Key synonyms in the literature include aikacin, amicacyn, amakacin, amicacin, and amicasin.

Evidence & Benchmarks

• Amikacin demonstrates robust activity against carbapenem-resistant Enterobacter cloacae and Klebsiella pneumoniae, which commonly harbor bla_NDM-1 and bla_KPC-2 carbapenemase genes (Chen et al., 2025).
• In a survey of 54 CREC isolates, 85.19% carried carbapenemase-encoding genes, with multidrug resistance including resistance to gentamicin, ciprofloxacin, and ceftazidime/avibactam (Chen et al., 2025).
• Amikacin remains effective in vitro where other aminoglycosides fail due to its resistance to most modifying enzymes, as confirmed by comparative resistance profiling (see mechanistic insights).
• Water solubility is ≥5.86 mg/mL at 25°C; DMSO and ethanol are unsuitable solvents (APExBIO).
• Stock solutions are optimally prepared by warming at 37°C for 10 minutes or using ultrasonic shaking (APExBIO).
• Amikacin must be stored at -20°C for stability; prepared solutions should be used promptly and not stored long-term (APExBIO).
• Amikacin is not for diagnostic or medical use; it is strictly for research applications (APExBIO).

Applications, Limits & Misconceptions

Amikacin (BAY416651) is an essential research tool for studies of antibiotic resistance mechanisms, especially in contexts where carbapenemase genes such as bla_NDM-1 and bla_KPC-2 are prevalent. It is employed to dissect the molecular basis of resistance, to benchmark susceptibility profiles, and to explore horizontal gene transfer among Enterobacteriaceae (Chen et al., 2025). The compound also serves as a reference for evaluating the efficacy of new antibiotic candidates and resistance-modifying agents. Its unique resistance profile enables high-precision studies in both molecular biology and translational microbiology (see protocols). This article provides updated insights beyond the practical protocols described in prior reviews.

Common Pitfalls or Misconceptions

• Amikacin is not effective against strains expressing AAC (6')-I type acetyltransferases, which can inactivate the drug by acetylation (APExBIO).
• It does not serve as a universal solution for all aminoglycoside-resistant bacteria; resistance profiling remains essential (Chen et al., 2025).
• Amikacin is unsuitable for use in medical or diagnostic settings; it is strictly intended for research applications (APExBIO).
• DMSO and ethanol are not appropriate solvents due to insolubility; only water at concentrations ≥5.86 mg/mL is recommended (APExBIO).
• Long-term storage of prepared solutions is not advised; use promptly after preparation to avoid loss of potency (APExBIO).

Workflow Integration & Parameters

For experimental workflows, Amikacin (BAY416651) is typically supplied as a solid by APExBIO (B3431). Prepare stock solutions at ≥5.86 mg/mL in ultrapure water. For higher concentrations, pre-warm to 37°C or use ultrasonic agitation for 10 minutes to facilitate dissolution. Store dry powder at -20°C in sealed containers. Avoid repeated freeze-thaw cycles. Shipping is performed on blue ice to preserve integrity. For susceptibility testing, employ broth microdilution or agar-based assays in accordance with CLSI/EUCAST guidelines. Reference studies commonly use concentrations ranging from 4 to 64 µg/mL, depending on bacterial species and assay design (Chen et al., 2025). For studies of resistance mechanisms, molecular techniques such as PCR, ERIC-PCR, and plasmid conjugation assays are recommended. Benchmarks for successful application include high purity (HPLC 98-99%), confirmed structure (C₂₂H₄₃N₅O₁₃), and documented storage/handling records (APExBIO).

Conclusion & Outlook

Amikacin (BAY416651) remains a cornerstone in the study of bacterial protein synthesis inhibition and antibiotic resistance mechanisms. Its semi-synthetic design confers resistance to most aminoglycoside-modifying enzymes, making it highly relevant for current MDR pathogen research, particularly in the context of carbapenem-resistant Enterobacter cloacae and Klebsiella pneumoniae (Chen et al., 2025). While the emergence of AAC (6')-I-mediated resistance highlights the need for continuous surveillance, the compound's robust performance in controlled experimental settings enables high-impact molecular and translational discoveries. Further extensions of this research will benefit from integrating amikacin with new diagnostic tools and resistance-modifying strategies.

For detailed compound specifications or to acquire the research-grade product, visit the Amikacin (BAY416651) Aminoglycoside Antibiotic product page from APExBIO. This article clarifies and updates prior application-focused overviews by embedding the latest epidemiological and mechanistic data.